Search Results

the kinetic factors that enhance in vivo efficacy beyond traditional potency metrics, as presented by Dr Dr. That's exactly what Dr. Dr. Submit your paper today to secure your work in Volume II ➤ Why Dr.

☕ We are excited to announce our rescheduled Dr. GPCR Virtual Cafe session with Dr.

🌟The Dr. GPCR event of the year is the 3rd edition of the Summit. Become a Dr. GPCR Ecosystem site member to attend the Summit, it’s free!

📅 Our FREE Dr. GPCR Summit 2022 is less than a month away!

July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics" Ross Bathgate Read more at the source #DrGPCR #GPCR #IndustryNews

A Broader Lens: Dr. GPCR As the co-founder of Dr.

Dr. Register and join your colleagues in September ➤ Why Dr. GPCR Premium Membership Gives You an Edge In a world filled with noise, Dr. ” - DrGPCR University Course Attendee Get a competitive advantage—Join Dr. Gain the insights, tools, and connections you need to excel in your field and make your mark.

Tomorrow is the day for another Dr. GPCR Virtual Cafe. This time with none other than Dr. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

June 2022 "We’re delighted to welcome Dr Ed Brennan as our new Vice President, Head of Clinical Development Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic

November 2021 Read more at the source #DrGPCR #GPCR #IndustryNews

Excited to hear Dr. Register here (FREE) https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe #drgpcr #gpcr #virtualcafe

Excited to hear Dr. automated micro-plate-based methods for quantifying #GPCR activation. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe

Come attend this month's virtual café talk to see the awesome work of Dr. Register here (FREE) https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

Join us and learn how to quantify your kinetic GPCR signaling from the expert himself: Dr. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

November 2021 "So proud and grateful to receive honorary doctorate yesterday from Karolinska Institute and celebrate with my family in Stockholm." Read more at the source #DrGPCR #GPCR #IndustryNews

Be sure to signup for the next Virtual Cafe of Dr. GPCR on the 24th of June! This time, the GPCRdb team ( Dr. David Gloriam , Dr. Reserve your spot for free at: https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #GPCR #GPCRs #DrGPCR

Join us for a fantastic introduction to GPCRdb with Dr. David Gloriam and Dr. Albert Kooistra. Register today: https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

Did you register for our next Dr. GPCR Virtual Cafe? Register today! Addgene's Dr. research or you want to share your materials, this is the place to go. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe

Join us for the first virtual cafe talk to hear about the amazing work that Dr. Brian Arey is doing. https://www.ecosystem.drgpcr.com/dr-gpcr-virtual-cafe/ #gpcr #drgpcr #virtualcafe

June 2022 "June 15, 2022 06:30 AM EDT - In 2016, Abbie Celniker was promoted to partner at Third Rock Ventures as the firm raised just over $600 million for its fourth fund. Since then, Celniker has helped usher in an additional fund and headed a few startups as interim CEO. Coming on its 15th year, Third Rock Ventures announced its sixth fund today — and largest one by far — at a whopping $1.1 billion. Adding it all up, Third Rock has raised $3.8 billion since its inception. That money has gone to some 60 biotechs, much of it as early funding." Read more at the source #DrGPCR #GPCR #IndustryNews

September 2022 "Morphine, the most widely used analgesic, relieves severe pain by activating the μ-opioid receptor (MOR), whereas naloxone, with only slight structural changes compared to morphine, exhibits inhibitory effect, and is used to treat opioid abuse. The mechanism by which the MOR distinguishes between the two is unclear. Molecular dynamics (MD) simulations on a 1-μs time scale and metadynamics-enhanced conformational sampling are used here to determine the different interactions of these two ligands with MOR: morphine adjusted its pose by continuously flipping deeper into the pocket, whereas naloxone failed to penetrate deeper because its allyl group conflicts with several residues of MOR. The endogenous peptide ligand endomorphin-1 (EM-1) underwent almost no significant conformational changes during the MD simulations. To validate these processes, we employed GIRK4S143T, a MOR-activated Gβγ-protein effector, in combination with mutagenesis and electrophysiological recordings. We verified the role of some key residues in the dynamic recognition of naloxone and morphine and identified the key residue I322, which leads to differential recognition of morphine and naloxone while assisting EM-1 in activating MOR. Reducing the side chain size of I322 (MORI322A) transformed naloxone from an inhibitor directly into an agonist of MOR, and I322A also significantly attenuated the potency of MOR on EM-1, confirming that binding deep in the pocket is critical for the agonistic effect of MOR. This finding reveals a dynamic mechanism for the response of MOR to different ligands and provides a basis for the discovery of new ligands for MOR at the atomic level." Read more at the source #DrGPCR #GPCR #IndustryNews

Mark your calendar for September and October 2024. Dr. Maria Waldhoer, JoAnn Trejo, and Anne Marie Quinn. Did you watch Episode #150 of the Dr. Dr. GPCR Matchmaking Mark Schmeizl, our Chief Matchmaker, can help you find your perfect match if you want Contact Mark today to get started. Dr.

Hello Dr. GPCR ecosystem members!  also the hiring manager for their open Principal Scientist, In Vitro Pharmacology role posted in the Dr Mark:  “Beth, why did you decide to join Crinetics?” Mark:  “Are there particular assay types of interest?” By: Mark Schmeizl Chief Matchmaker at Dr. GPCR

Mark your calendars for September and October 2024! We are excited to announce that Dr. Dr. GPCR Podcast Exciting news! Episode 152 with Dr. Our most recent episode features our very own Dr. GPCR Board. Tune in and enjoy! Dr. GPCR Matchmaking Meet Mark Schmeizl, our Chief Matchmaker. Mark your calendar for the GPCRs as Therapeutic Targets symposium on October 11th, 2024.

Join our upcoming Dr. GPCR University hands-on workshop with Dr.  The workshop includes: Four x 2-hour Zoom sessions One-on-one meeting with Dr. Hoare Access to Dr. Dr. Also, if you are looking to hire or be hired, Mark Schmeizl can help you find your perfect match. Contact Mark today to get started.

Join our upcoming Dr. GPCR University hands-on workshop with Dr.  The workshop includes: Four x 2-hour Zoom sessions One-on-one meeting with Dr. Hoare Access to Dr. Dr. Also, Mark Schmeizl can help you find your perfect match if you want to hire or be hired. Contact Mark today to get started.

They both mark critical moments in humanity’s centuries-long quest to control physiology—and they bookend In this exclusive foundational-level lecture, Dr. Dr. Kenakin also celebrates the giants on whose shoulders we stand—A.J.

GPCR University Today marks the final day of the Dr. Dr. GPCR Podcast We have thrilling news—Episode 153 of the Dr. GPCR Podcast featuring Dr. Dr. GPCR Matchmaking Read Mark's job spotlight article for a Principal Scientist in In Vitro Pharmacology Mark recently discussed this exciting opportunity with Beth Fleck, Director of In Vitro Pharmacology

Norton Cheng and Dr. Dr. Robert J Lefkowitz and team's study 'GPCR signal transduction: β-arrestin activates ERK MAPK.' Dr. Thomas P. Our confirmed speakers are Dr. Xavier Leroy, Dr. Brian Arey, and Dr. J. Silvio Gutkind. You can find more information about them on the Live Talks page and mark your calendar HERE.